Bristol Myers forecasts steeper drop in 2025 revenue, shares fall
By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its older drugs,
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.
Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.
Bristol sees sharper 2025 revenue drop after better-than-forecast Q4
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its older drugs.
Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price gain of more than 20%, while most of the group has been flat or down.
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion in costs through 2027. That initiative came after the company began executing a plan to reduce costs by $4 billion.
Bristol Myers forecasts 2025 revenue below estimates after strong quarter
By Michael Erman (Reuters) -Bristol Myers Squibb on Thursday posted better-than-expected fourth-quarter earnings, but said its 2025 revenue would fall more sharply than Wall Street had forecast due to generic competition for some of its older drugs.
Bristol Myers expects to deliver additional ~$2B in cost savings by 2027-end
Squibb is expanding its existing strategic productivity initiative to include approximately $2B in additional annualized
Bristol-Myers Squibb Stock Falls on Surprisingly Weak Guidance
Shares in Bristol-Myers Squibb fell more than 4% in premarket trading Thursday, after the drug maker gave 2025 guidance that undershot analyst expectations. Bristol expects sales of about $45.5 billion in 2025,
Bristol Myers misses expectations for 2025 guidance, shares fall
Bristol-Myers Squibb Company (NYSE:BMY) slid more than 2% in premarket trading Thursday after the company's guidance for 2025 missed average analyst expectations.
Liam Manning: Bristol City boss says run of three games in a week is 'madness'
Bristol City's schedule is "madness" says head coach Liam Manning as they face three Championship games in seven days.
Bristol Sees Pricing Pressure Weighing on 2025 Outlook
Bristol Myers Squibb Co. forecast 2025 sales and profit below Wall Street’s expectations — a sign that declining sales of ...
Grave problems remain over missing cash in Bristol City Council team helping refugees
Serious concerns over missing cash in a Bristol City Council team supporting refugees have started to be addressed, but there ...
How did Bristol City do in January transfer window? Fans have their say
Ed: As usual, a disappointing lack of ambition from the senior management to push hard for promotion. They blame the transfer ...
Live: M5 crash causing tailbacks near Bristol at rush hour
A lane is closed on the M5 after a crash near Bristol this afternoon, Thursday, February 6. The collision took place on the ...
Bristol City team news ahead of Swansea as Manning shares Pring and Williams availability update
Liam Manning has confirmed that Cam Pring is "back on the grass" but admits that Bristol City's games against Swansea City, ...
fingerlakes16h
Fairport man charged with theft of services at Bristol Mountain
Ontario County Sheriff’s deputies arrested a Fairport man at Bristol Mountain Ski Resort on Wednesday evening following an ...
Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...